Evaluation of BGJ398, a Fibroblast Growth Factor Receptor 1-3 Kinase Inhibitor, in Patients With Advanced Solid Tumors Harboring Genetic Alterations in Fibroblast Growth Factor Receptors: Results of a Global Phase I, Dose-Escalation and Dose-Expansi
about
A Phase Ib Open-Label Multicenter Study of AZD4547 in Patients with Advanced Squamous Cell Lung Cancers.Polyclonal Secondary FGFR2 Mutations Drive Acquired Resistance to FGFR Inhibition in Patients with FGFR2 Fusion-Positive Cholangiocarcinoma.Advances and challenges in targeting FGFR signalling in cancer.Investigational drugs targeting fibroblast growth factor receptor in the treatment of non-small cell lung cancer.Emerging molecular therapeutic targets for cholangiocarcinoma.Clinical trials of tyrosine kinase inhibitors for lung cancer in China: a reviewIntrinsic fluorescence of the clinically approved multikinase inhibitor nintedanib reveals lysosomal sequestration as resistance mechanism in FGFR-driven lung cancer.Targeting Novel but Less Common Driver Mutations and Chromosomal Translocations in Advanced Non-Small Cell Lung Cancer.Comprehensive Molecular Characterization of Muscle-Invasive Bladder Cancer.Relevance of genetic alterations in squamous and small cell lung cancer.A Phase 1 study of ARQ 087, an oral pan-FGFR inhibitor in patients with advanced solid tumours.Bladder-cancer-associated mutations in RXRA activate peroxisome proliferator-activated receptors to drive urothelial proliferation.Identifying and Targeting Sporadic Oncogenic Genetic Aberrations in Mouse Models of Triple Negative Breast Cancer.Phase II Study of BGJ398 in Patients With FGFR-Altered Advanced Cholangiocarcinoma.Precision medicine for urothelial bladder cancer: update on tumour genomics and immunotherapy.Resistance mediated by alternative receptor tyrosine kinases in FGFR1-amplified lung cancer.2-Aminopyrimidine Derivatives as New Selective Fibroblast Growth Factor Receptor 4 (FGFR4) Inhibitors.Different stages in drug development for muscle-invasive bladder cancer.FGFR1 signaling potentiates tumor growth and predicts poor prognosis in esophageal squamous cell carcinoma patients.Next-generation sequencing in non-muscle-invasive bladder cancer-a step towards personalized medicine for a superficial bladder tumor.Liquid Biopsy-Analysis of Circulating Tumor DNA (ctDNA) in Bladder Cancer.An FGFR3/MYC positive feedback loop provides new opportunities for targeted therapies in bladder cancers.Mechanisms of rapid cancer cell reprogramming initiated by targeted receptor tyrosine kinase inhibitors and inherent therapeutic vulnerabilities.Fusions in solid tumours: diagnostic strategies, targeted therapy, and acquired resistance.RAS-MAPK reactivation facilitates acquired resistance in FGFR1-amplified lung cancer and underlies a rationale for upfront FGFR-MEK blockade.A Phase 1 Study of LY2874455, an Oral Selective pan-FGFR Inhibitor, in Patients with Advanced Cancer.Addressing the challenges of applying precision oncology.Emerging application of genomics-guided therapeutics in personalized lung cancer treatment.Breakthroughs in the treatment of advanced squamous-cell NSCLC: not the neglected sibling anymore?FGFR3 mRNA overexpression defines a subset of oligometastatic colorectal cancers with worse prognosisSuccessful response to the combination of immunotherapy and chemotherapy in cholangiocarcinoma with high tumour mutational burden and PD-L1 expression: a case report
P2860
Q38725360-BDDC5750-76A7-4377-8944-38B956EA7B4FQ38776411-714FC476-6AD5-4F20-9718-937F9354F486Q39183442-3E9E9A17-01D6-4CA6-873A-81AE458690B7Q39226762-808C5181-3076-4B60-8157-0F06BA4C55B6Q39227356-04131B61-4A8C-4DA1-A485-D1E618A8FCA8Q41292062-CAC5E219-240A-4416-B63E-9AEB2C678020Q41525071-B9B5C427-62FD-49DC-829A-7170C1BC22C2Q42369856-1AFCD87B-6D0E-4A7F-8C21-2A21D4D6D8C7Q42516513-499CCCEF-2D0D-4417-8DEE-D61464A18448Q44483486-FEE6D227-4F91-490E-82C5-162B4671F580Q45069154-B1C14B99-890D-4536-A74C-13EB4CE188E1Q47142673-7E5E1302-A19D-4375-8056-9D5E1BEE8D10Q47285585-3319BCE4-9660-40DC-BACC-276C81FB230CQ47403256-D2C61199-EC8C-445F-9244-9725C39C364FQ47406496-C0AD7665-8196-4510-B15B-36D3B09F08CEQ47715159-91BD1644-ADEC-40E5-8E23-B1ACA9E83956Q47887075-9FDFC15A-2883-458A-83AA-81180F9B81EFQ48022703-F9C275C1-68BF-4B92-B4E5-B0AC2C2AF4A7Q48564245-90DA3FF6-5E19-4181-B7C8-AFD236622700Q49206807-CF9E30F5-B91D-441F-B86F-E86B7BA63387Q49728493-B10EC57E-3E8E-4E22-A145-07A9CB06B726Q49791794-811FDBEE-35C5-46E2-A027-2B1C9FBB433CQ49843607-567E4A94-ADD1-4A98-B99A-9827AAF75EECQ50251062-77226DDE-D805-4C13-ADB6-7714EE37DAB3Q52589214-922D0499-0C0B-4D7C-A8C3-41D13AEAFD9AQ52766440-A5854EA6-8AEE-46EF-8807-543FA0D2C165Q55314165-204F0162-D5F3-4BDB-81EB-3F64C4E6E5DFQ55314894-76DFFFD2-C75E-45FB-AB51-915BA7E5B5BBQ55341383-978733F9-ACC0-4826-9062-36C5C88A9920Q58780441-97AABC40-D746-4DCF-82D7-EF6B26E8591BQ59127261-A4AFA7B6-E86B-488B-B7B3-8B45C3435BBE
P2860
Evaluation of BGJ398, a Fibroblast Growth Factor Receptor 1-3 Kinase Inhibitor, in Patients With Advanced Solid Tumors Harboring Genetic Alterations in Fibroblast Growth Factor Receptors: Results of a Global Phase I, Dose-Escalation and Dose-Expansi
description
2016 nî lūn-bûn
@nan
2016年の論文
@ja
2016年論文
@yue
2016年論文
@zh-hant
2016年論文
@zh-hk
2016年論文
@zh-mo
2016年論文
@zh-tw
2016年论文
@wuu
2016年论文
@zh
2016年论文
@zh-cn
name
Evaluation of BGJ398, a Fibrob ...... se-Escalation and Dose-Expansi
@en
Evaluation of BGJ398, a Fibrob ...... se-Escalation and Dose-Expansi
@nl
type
label
Evaluation of BGJ398, a Fibrob ...... se-Escalation and Dose-Expansi
@en
Evaluation of BGJ398, a Fibrob ...... se-Escalation and Dose-Expansi
@nl
prefLabel
Evaluation of BGJ398, a Fibrob ...... se-Escalation and Dose-Expansi
@en
Evaluation of BGJ398, a Fibrob ...... se-Escalation and Dose-Expansi
@nl
P2093
P356
P1476
Evaluation of BGJ398, a Fibrob ...... ation and Dose-Expansion Study
@en
P2093
D Ross Camidge
Dale Porter
Diana Graus-Porta
Francois Ringeisen
G Gary Tian
Geoffrey I Shapiro
Howard Burris
Jan H M Schellens
Jean-Pierre Delord
Jose Manuel Perez Garcia
P304
P356
10.1200/JCO.2016.67.2048
P407
P577
2016-11-21T00:00:00Z